7Baggers
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

Eliem Therapeutics, Inc
(NASDAQ:ELYM) 

ELYM stock logo

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems in the United States. The compan...

Founded: 2018
CEO: Bob Azelby  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
Eliem Therapeutics Op Cashflow Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -2.25-1.93-1.6-1.28-0.96-0.64-0.320
Eliem Therapeutics Free Cashflow Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -2.25-1.93-1.6-1.28-0.96-0.64-0.320
Eliem Therapeutics Cash Per Share ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 00.671.342.012.683.354.034.7
Eliem Therapeutics (GAAP) P/E ratio ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -2.16-1.85-1.54-1.23-0.92-0.62-0.310
Eliem Therapeutics P/B ratio ttm
202209 202210 202211 202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 00.10.210.310.410.510.620.72
No extra charts and metrics for this ticker.